Elan to sell European assets

pharmafile | December 12, 2003 | News story | Sales and Marketing Elan 

Indebted Irish pharmaceutical company Elan has confirmed that it is in talks to sell part of its European operations.

The company said the sale would mainly consist of its European sales and marketing business, but would not confirm if or when the transaction might be completed.

Elan was the biggest company on the Irish stock exchange two years ago but an admission from then chief executive Donal Geaney that two off-balance sheet expenses had not been consolidated triggered a downwards spiral in investor confidence from which the company has still not recovered.

The company’s accountancy practices are still the subject of a Securities and Exchange Commission investigation, which analysts expect to be completed by mid-2004.

Earlier this month Elan completed the sale of its four pain products and related assets for $101.8 million. North-Carolina-based specialty pharmaceutical company aaiPharma purchased the rights to Roxicodone, OramorphSR, Roxanol and Duraclon after making a cash payment to Elan of $50.4 million and assuming $51.4 million of Elan’s product-related payments.

 

Related Content

Perrigo image

Perrigo acquires Omega for $4.5 billion

In a deal worth $4.5 billion Perrigo has announced the acquisition of over-the-counter (OTC) drugmaker …

edelman

Edelman buys Elan to ‘challenge’ the French PR industry

Edelman has swooped in on fellow PR firm Elan to create a ‘new player’ in …

Elan image

Perrigo pays $8.6 billion for Elan

Generics firm Perrigo has snapped up Ireland-based Elan in a multi-billion dollar deal, ending a …

Latest content